SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc.
MNTA 52.480.0%Oct 2 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2511)9/25/2010 4:46:35 PM
From: DewDiligence_on_SI  Read Replies (1) of 3027
 
MNTA ‘ReadMeFirst’ updated:

despite what Teva says, US Copaxone patents expire May 2014 (not Sep 2015);
according to NVS, Lovenox is highest-margin product in Sandoz’s portfolio;
FDA approves NVS’ Gilenya for first-line RRMS;
musings on Gilenya’s commercial prospects;
Merck KGaA’s Cladribine rejected in EU;
index to FDA labels of approved MS drugs;
new version of “What’s New in the Anticoagulant Market.”

siliconinvestor.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News